As of December 31, 2022, the Company had cash and cash equivalents and deposits in the amount of $12.6 million, compared to $32.2 million at December 31, 2021. PolyPid expects that this cash balance will be sufficient to fund operations well into the third quarter of this year.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PYPD:
- PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
- PolyPid provides regulatory update for D-PLEX100
- PolyPid announces publication of Phase 2 clinical trial analysis of D-PLEX100
- PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
